ZA201304139B - Combination - Google Patents

Combination

Info

Publication number
ZA201304139B
ZA201304139B ZA2013/04139A ZA201304139A ZA201304139B ZA 201304139 B ZA201304139 B ZA 201304139B ZA 2013/04139 A ZA2013/04139 A ZA 2013/04139A ZA 201304139 A ZA201304139 A ZA 201304139A ZA 201304139 B ZA201304139 B ZA 201304139B
Authority
ZA
South Africa
Prior art keywords
combination
Prior art date
Application number
ZA2013/04139A
Other languages
English (en)
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of ZA201304139B publication Critical patent/ZA201304139B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/04139A 2011-01-11 2013-06-06 Combination ZA201304139B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11
PCT/US2012/020863 WO2012097021A1 (en) 2011-01-11 2012-01-11 Combination

Publications (1)

Publication Number Publication Date
ZA201304139B true ZA201304139B (en) 2014-02-26

Family

ID=46507420

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/04139A ZA201304139B (en) 2011-01-11 2013-06-06 Combination

Country Status (15)

Country Link
US (6) US20130288984A1 (cg-RX-API-DMAC7.html)
EP (1) EP2663189B1 (cg-RX-API-DMAC7.html)
JP (1) JP6100700B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140053836A (cg-RX-API-DMAC7.html)
CN (1) CN103298345B (cg-RX-API-DMAC7.html)
AU (1) AU2012205601B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013017722A2 (cg-RX-API-DMAC7.html)
CA (1) CA2824201A1 (cg-RX-API-DMAC7.html)
EA (1) EA029000B1 (cg-RX-API-DMAC7.html)
ES (1) ES2689760T3 (cg-RX-API-DMAC7.html)
IL (1) IL227097B (cg-RX-API-DMAC7.html)
MX (1) MX356704B (cg-RX-API-DMAC7.html)
SG (2) SG191724A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012097021A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201304139B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016006976A2 (pt) * 2013-10-01 2017-08-01 Novartis Ag combinação
JP6568093B2 (ja) * 2013-11-07 2019-08-28 デシフェラ ファーマシューティカルズ,エルエルシー ガンの処置に有用なtie2キナーゼの阻害方法
MX2020008015A (es) 2018-01-31 2020-10-16 Deciphera Pharmaceuticals Llc Terapia de combinación para el tratamiento de la mastocitosis.
EP3746059A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
KR20250057151A (ko) 2019-12-30 2025-04-28 데시페라 파마슈티칼스, 엘엘씨 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
CA2560691A1 (en) * 2004-03-24 2005-10-13 Abbott Laboratories Tricyclic pyrazole kinase inhibitors
WO2006040649A1 (en) 2004-10-13 2006-04-20 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
EP2275096A3 (en) * 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
EP2004165A2 (en) 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
KR20090059126A (ko) 2006-08-25 2009-06-10 코우가 바이오테크놀로지, 인크. 암을 치료하기 위한 방법 및 조성물
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
WO2008094321A2 (en) * 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
PE20080859A1 (es) 2006-10-13 2008-09-04 Basf Ag Hidratos de 2-cloro-5-[3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil]-4-fluor-n-[[metil(1-metiletil)amino]sulfonil]benzamida
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
BRPI1006896B1 (pt) 2009-01-30 2022-05-24 Novartis Ag Cloridrato de n-{(1s)-2-amino-1-[(3-fluorfenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h- pirazol-5-il)-2-tiofenocarboxamida cristalino, composição farmacêutica compreendendo o mesmo e uso do dito composto para tratar ou diminuir a gravidade de câncer e artrite
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Cyp17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
WO2011044415A1 (en) 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
WO2012135759A1 (en) 2011-04-01 2012-10-04 Genentech, Inc. Combinations of akt inhibitor compounds and abiraterone, and methods of use
EP2704699A1 (en) 2011-05-03 2014-03-12 University of Rochester Methods for treating prostate cancer
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
SI2766381T1 (sl) 2011-10-10 2016-11-30 Zach System, Z.I. Postopek za pripravo 17-substituiranih steroidov
SMT201900708T1 (it) 2011-11-30 2020-01-14 Astrazeneca Ab Trattamento di combinazione di un cancro
KR20230170108A (ko) 2012-06-04 2023-12-18 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
KR101797415B1 (ko) 2013-10-01 2017-11-13 노파르티스 아게 암의 치료를 위한 아푸레세르팁과 조합된 엔잘루타미드

Also Published As

Publication number Publication date
IL227097B (en) 2018-02-28
JP2014507412A (ja) 2014-03-27
EA029000B1 (ru) 2018-01-31
AU2012205601B2 (en) 2016-03-24
US20170100449A1 (en) 2017-04-13
US20130288984A1 (en) 2013-10-31
WO2012097021A1 (en) 2012-07-19
CA2824201A1 (en) 2012-07-19
CN103298345B (zh) 2016-12-14
EP2663189A4 (en) 2014-06-11
BR112013017722A2 (pt) 2016-07-12
KR20140053836A (ko) 2014-05-08
US20120258933A1 (en) 2012-10-11
US20160375086A1 (en) 2016-12-29
EA201391027A1 (ru) 2014-01-30
MX356704B (es) 2018-06-11
SG10201600077RA (en) 2016-02-26
MX2013008074A (es) 2013-08-09
US10449226B2 (en) 2019-10-22
US20150119337A1 (en) 2015-04-30
JP6100700B2 (ja) 2017-03-22
EP2663189A1 (en) 2013-11-20
ES2689760T3 (es) 2018-11-15
SG191724A1 (en) 2013-08-30
US20160022641A1 (en) 2016-01-28
CN103298345A (zh) 2013-09-11
EP2663189B1 (en) 2018-07-04
AU2012205601A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
DK3798230T3 (en) Terapeutiske antistoffer
GB201104263D0 (en) Bio-resins
ZA201304139B (en) Combination
PL2606715T3 (pl) Kombinacja prasująco-owijająca
GB201103926D0 (en) Lock-alarm
AU5031P (en) BESYS Beschorneria yuccoides
GB201121105D0 (en) Combination
GB201117693D0 (en) Combination
GB201116007D0 (en) Combination
GB201106339D0 (en) Combination
GB201101269D0 (en) Hyging
GB201115381D0 (en) Flood-saver
GB201106857D0 (en) Laptopkey
GB201106769D0 (en) In-soap
GB201106650D0 (en) Customation
GB201104362D0 (en) Webhook
GB201102755D0 (en) Protectaridge
GB201103301D0 (en) Circair
GB201102013D0 (en) Aimspray easyreach
GB201107157D0 (en) Corcost-zz500
GB201101931D0 (en) Kerbknight
GB201101675D0 (en) i-mc
GB201107154D0 (en) Corcost-zz300
GB201100364D0 (en) Aimspray
GB201100308D0 (en) CrossPic